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Abstract
Introduction Cancer and blood disorders in children are rare. The progressive improvement in survival over the last decades 
largely relies on the development of international academic clinical trials that gather the sufficient number of patients glob-
ally to elaborate solid conclusions and drive changes in clinical practice. The participation of Spain into large international 
academic trials has traditionally lagged behind of other European countries, mainly due to the burden of administrative tasks 
to open new studies, lack of financial support and limited research infrastructure in our hospitals.
Methods The objective of ECLIM-SEHOP platform (Ensayos Clínicos Internacionales Multicéntricos-SEHOP) is to over-
come these difficulties and position Spain among the European countries leading the advances in cancer and blood disorders, 
facilitate the access of our patients to novel diagnostic and therapeutic approaches and, most importantly, continue to improve 
survival and reducing long-term sequelae. ECLIM-SEHOP provides to the Spanish clinical investigators with the necessary 
infrastructural support to open and implement academic clinical trials and registries.
Results In less than 3 years from its inception, the platform has provided support to 20 clinical trials and 8 observational 
studies, including 8 trials and 4 observational studies where the platform performs all trial-related tasks (integral support: 
trial setup, monitoring, etc.) with more than 150 patients recruited since 2017 to these studies. In this manuscript, we provide 
baseline metrics for academic clinical trial performance that permit future comparisons.
Conclusions ECLIM-SEHOP facilitates Spanish children and adolescents diagnosed with cancer and blood disorders to 
access state-of-the-art diagnostic and therapeutic strategies.
Keywords Pediatric hematology and oncology · Clinical trials · Drug development · Clinical research
Introduction
Childhood cancer
In Spain, a new case of cancer is diagnosed annually for 
every 6500 children under 15 years of age. This represents 
1100 new cases between 0 and 14 years and 450 between 15 
and 19 [1], only a small fraction of the nearly quarter of mil-
lion new invasive cancer diagnosed in our country every year 
for the whole population if we include adults and the elderly 
[2]. Cancer represents the first cause of death due to disease 
in children. Nonetheless, survival has considerably improved 
within the past 30 years and current overall survival in Spain 
L. Moreno and A. Fernández-Teijeiro are both the co-senior 
authors.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1209 4-019-02221 -9) contains 
supplementary material, which is available to authorized users.
 * L. Moreno 
 lucas.moreno@vhebron.net
Extended author information available on the last page of the article
1764 Clinical and Translational Oncology (2019) 21:1763–1770
1 3
is 80% at 5 years [3]. These survival figures are still lower 
than data available for other countries of Western Europe 
such as Germany or France (> 85% at 5 years) [4]. Despite 
important reductions in mortality, childhood cancer survi-
vors still face an unacceptable burden of long-term toxicities 
and sequelae [5].
Role of the Spanish Society of Pediatric Hematology 
and Oncology (SEHOP)
In Spain, the Registro Español de Tumores Infantiles (RETI) 
was created in 1979, a milestone in Spanish pediatric oncol-
ogy that has collected data on more than 26,000 patients 
[1]. In 2008, the Sociedad Española de Oncología Pediátrica 
(SEOP) and the Sociedad Española de Hematología 
Pediátrica (SEHP) merged into SEHOP bringing together 
250 members (mainly pediatricians, hematologists, pediat-
ric surgeons and radiotherapists) from more than 40 centers 
distributed throughout the national geography. The aim of 
SEHOP (http://www.sehop .org) is, on one hand, to promote 
the development of pediatric hematology and oncology in 
Spain in its facets of prevention, best medical care, training, 
teaching and research; and, on the other hand, to ensure the 
right that every child and adolescent have to be assisted in 
institutions that have the necessary means and sufficiently 
qualified health personnel using therapeutic schemes that are 
nationally or internationally recognized [6].
Role of clinical trials in pediatric oncology
International collaboration and collaborative clinical trials 
are the main factors contributing to the major improvements 
in survival for many childhood cancers [7–9]. For children 
and adolescents with cancer, participation in international 
clinical trials has become the standard of care, improving 
and ensuring the quality of the treatment received, as well as 
greatly increasing the scientific value of the work at a global 
level [10]. As stated in the document European Standards 
of Care for Children with Cancer [6]: “All children with 
cancer should be treated according to the best available 
treatment protocols. There is general agreement that this is 
best provided within units that are active in clinical research 
and cancer registration processes. When available, children 
should be offered the opportunity to participate in relevant 
clinical trials that aim to improve the optimal treatment for 
all children”.
Pediatric international clinical trials in Spain: 
current situation
Until recently, the participation of Spain into pediatric 
international clinical trials has lagged behind from that 
of European countries [11]. After the implementation of 
the European Clinical Trials Directive in 2001 (Directive 
2001/20/EC) [12], the model to set up academic clinical tri-
als in Europe was that an international sponsor, generally 
a university or academic research center, takes the central 
roles of a sponsor, and relies on a network of national coor-
dinating centers (NCC), which act as national sponsors in 
each of the member states where the trial is open. These 
NCCs have to undertake a variety of trial-related tasks 
such as regulatory submissions, yearly reports to ethics and 
competent authorities, site selection and site initiation and 
often monitoring or pharmacovigilance activities. For the 
first 10 years after this implementation, the meager research 
infrastructure at our country posed significant challenges for 
Spanish institutions (either universities, hospitals, research 
foundations or research institutes) to take on this NCC role. 
However, over the past 5 years, several factors have contrib-
uted to the improvement of the participation of Spain into 
international clinical trials:
1. The transition from individual Spanish institutional 
efforts to open large international trials, to a central 
Spanish pediatric infrastructure for implementing and 
developing international clinical trials, first created in 
2014 and named ARCAHI (Armonización en el tratami-
ento del cáncer infantil y las hemopatías en España), and 
from 2017 further developed into the ECLIM-SEHOP 
platform (Ensayos Clínicos Internacionales Multicéntri-
cos-SEHOP).
2. The progressive incorporation of five large pediatric 
Spanish centers from 2010 onwards into the Innovative 
Therapies for Children with Cancer Consortium (ITTC) 
(http://www.itcc-conso rtium .org), a European network 
focused on early phase clinical trials of new drugs whose 
aim is to develop novel therapies for the treatment of 
pediatric and adolescent cancers in cooperation with 
regulatory bodies, pharmaceutical companies, parents 
and patients.
3. The close collaboration between SEHOP and other 
Spanish cancer research collaborative groups, such as 
the Grupo Español de Investigación en Sarcomas (GEIS, 
http://www.grupo geis.org), that has opened the door to 
pediatric cancer units to adhere to large international tri-
als that might not been possible otherwise (e.g., Euroew-
ing 2012, IS-GEIS-OS-02).
4. The changes in 2007 in the European legislation favoring 
the development of new anticancer agents in children by 
means of the pediatric investigational plan (PIP) requi-
site for pharmaceutical companies [13] and the imple-
mentation in Spain in 2015 of the updated clinical trial 
regulation (Real Decreto 1090/2015, 4th December) [14] 
that facilitates the administrative burden and reduces the 
costs for opening new academic studies, among other 
changes;
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5. The increasing active partnership of the SEHOP work-
ing groups with International Collaborative Groups trial 
such as SIOPEN, Euronet, SIOP-BTG, SIOPEL, I-BFM, 
EICNHL or the Histiocyte Society and the leadership 
of Spanish investigators in European networks [e.g., the 
LINES trial (NCT01728155) in neuroblastoma being the 
first international trial in pediatric oncology sponsored 
by a Spanish institution (IIS La Fe, Valencia)].
The objective of this manuscript is to report the setup 
of the new collaborative platform ECLIM-SEHOP, as well 
as establishing baseline metrics for academic clinical trial 
performance that permits future comparisons.
Materials and methods
This manuscript is focused on providing descriptive met-
rics of all the activities conducted by the ECLIM-SEHOP 
platform from 2017 to 2019. The ECLIM-SEHOP platform 
database was queried for this purpose. Date cutoff for analy-
sis was 31st July 2019. Data reported includes the setup of 
the platform, a description of its standard operating pro-
cedures (SOPs), a description of the trial portfolio and a 




Following on the initial work of the ARCAHI initiative and 
the clinical trials office of SEHOP, the ECLIM-SEHOP 
platform was started in 2017 and fully established from 
2018 onwards. The initial setup phase comprised the 
establishment of the platform organigram, development 
of SOPs for defining the evaluation and selection criteria 
for the studies to support and defining the roles of the 
members of the platform (Supplementary Document 1), 
and lastly the review and approval of the structure and 
SOPs by the SEHOP Executive Board. To have the capac-
ity and expertise to perform all trial-related tasks required 
by international sponsors, an agreement with a contract 
research organization (CRO) experienced in the conduct 
of academic clinical trials was sought (http://www.sofpr 
omed.com).
Objectives of ECLIM‑SEHOP
The objectives of the platform are:
1. To establish the infrastructure to allow the participation 
of Spain into international academic collaborative clini-
cal trials.
2. To increase the number of academic international clini-
cal trials open in Spain.
3. To improve the setup (timelines) and conduct (quality 
control) of academic and international clinical trials 
open in Spain.
4. To undertake trial-related activities as required from the 
international sponsors and national investigators:
4.1 Regulatory submissions to Spanish competent 
authority (AEMPS) and research ethics committee 
(CEIm).
4.2 Contract management and site setup (Site monitor-
ing, pharmacovigilance, management of biological 
samples, central review of imaging and pathology).
Table 1  ECLIM-SEHOP trial metrics
CA competent authorities, EC ethics committee
Trial portfolio Number of clinical trials open for recruitment per year (total and with integral support)
Number of observational studies open for recruitment per year (total and with integral support)
Number of patient registries open for recruitment per year (total and with integral support)
Total number of ongoing clinical trials (total and with integral support)
Total number of ongoing observational studies (total and with integral support)
Total number of patient registries (total and with integral support)
Trial recruitment (for trials and studies with 
integral support)
Total number of new patients recruited per year in clinical trials, observational studies and 
patient registries
For each clinical trial, percentage of actual recruitment from planned recruitment
Trial opening timelines (for trials with integral 
support)
Time from EC/CA submission to EC/CA approval
Time from EC/CA approval to first site open
Time from EC/CA approval to > 50% of the sites open
Time from first site open to first patient recruited
Time from EC/CA submission to first patient recruited
Time from first international site open to first Spanish site open
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Structure and functioning of ECLIM‑SEHOP
ECLIM-SEHOP is hierarchically structured (Fig. 1). For 
each new clinical trial proposal, a clinical investigator 
member of SEHOP completes a “new trial form” which is 
submitted to the platform providing a summary of the trial 
and details of the level of support required. The Scientific 
Directors, together with an independent reviewer member of 
SEHOP, and external reviewers when needed, evaluate the 
feasibility and scientific quality of the proposal and decide to 
accept/reject the participation of the platform in the proposal 
(Fig. 2). The platform prioritizes peer-reviewed academic 
international phase II-III clinical trials from world-wide rec-
ognized research groups that are addressed to children with 
prevalent hematological or oncological conditions and can 
be quickly and effectively translated into clinical practice 
(Supplementary Document 2 lists all selection criteria and 
the applicant investigator requisites).
Support for clinical trials
The platform also provides support to investigators for 
regulatory advice, center selection, central review of imag-
ing and, sample shipment and biomarker analyses when 
required.
ECLIM‑SEHOP clinical trial portfolio
From January 2017, the platform has provided support 
to 20 academic clinical trials, 8 observational studies 
and patient registries, 1 imaging platform (https ://imagi 
ng.sehop cloud .org) and 2 clinical databases. Of those, the 
Fig. 1  ECLIM-SEHOP Organi-



















Evaluation by the Scientific 
Directors, Scientific 
Collaborators and External 
Reviewers
(2 weeks)
The platform communicates 
with the Investigator for the 
Decision of Go / No Go
- The SEHOP Investigator contacts with
the Scientific Directors and sends
proposal
- The proposal is evaluated by the
Scientific Directors, Collaborators and
External Reviewers (when applicable)
- The platform evaluates the validity and
scientific interest of the trial and
feasibility and applicability in our country
- The decision is shared between the
platofrm and the respective research
SEHOP sub-group according to SEHOP
Guidelines
- The Scientific Directors contact back
with the Investigator for clarifications (if
needed) and the decision for setting the
study up in Spain through the platform
- In case this is a positive decision, the
plaftorm initiates the negotiations with
the CRO for set-up process
- The applicant investigator acquires the
national coordinator responsibilities and
adheres to the ECLIM-SEHOP requisites
for granted researches (Supplementary
Document 2)
Fig. 2  Decision chart of new clinical trials proposals for setup and implementation through the ECLIM-SEHOP platform. CRO Clinical 
Research Organization
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platform provides integral support (e.g., all trial-related 
activities are conducted by the platform) for 8 clinical 
trials and 4 observational studies and patient registries 
(Fig. 3). These studies, which are internationally recog-
nized as best standard of care in Europe, cover children 
and adolescents with leukemia (acute lymphoblastic leuke-
mia [ALL], acute myeloid leukemia, infant ALL, bilineage 
acute leukemia, relapsed ALL), lymphoma (Hodgkin and 
non-Hodgkin lymphoma), Langerhans cell histiocytosis, 
brain tumors (ependymoma, medulloblastoma, diffuse 
intrinsic pontine glioma, low-grade glioma) and extracra-
nial solid tumors (renal tumors, neuroblastoma, and soft 
tissue sarcomas). But also they focus on key transversal 
aspects such as allogeneic stem cell transplant, imple-
mentation of follow-up of late effects of childhood cancer 
(SIOPE survivors passport project; http://www.survi vorsh 
ippas sport .org). Fundación SEHOP is also covering the 
costs of clinical trial insurance for academic clinical trials 
conducted in Spain in pediatric cancer and blood disor-
ders, including early clinical trials (phase 1 and 2) from 
national (CELYVIR [15]) or international academic initia-
tives such as MEMMAT [16] or the trials from the ITCC 
consortium  (BIOMEDENCT02233049,  VINILONCT01887522, 
BEACON [17],  CRISPEUDRACT 2015-005437-53, ESMART 
NCT02813135) also supporting the opening of new therapeutic 
options for children with relapsed and refractory cancers 
in our country.
During 2019, new studies for soft tissue sarcomas, 
bone marrow failures and chronic neutropenias will also 
be adopted.
Integral support is provided to 8 clinical trials and 4 
observational studies. This means that all national co-
sponsor activities are performed by the ECLIM-SEHOP 
platform, including trial setup, regulatory submissions and 
contracts or monitoring.
Recruitment metrics
In the five clinical trials with integral support that are 
open, 169 patients have been recruited from January 2017 
onwards. Metrics for timelines for opening clinical trials 
are shown in Table 2.
20 Clinical Trials
8 Observational Studies and Patient Registries
Partial Support
(16 studies)
12 CLINICAL TRIALS (INDICATION)
- RMS 2005 (Rhabdo and Non-Rhabdomyosarcomas)
- LCHIV (Langerhans Cell Histiocytosis)
- SIOP-PNET 5 (Medulloblastoma)
- NHL-RITUX 2010 (Non-Hodgkin Lymphoma)
- OMS/DES  2011 (Opsoclonus-Myoclonus/Neuroblastoma)
- VINILO (Low grade glioma)
- BIOMEDE (Diffuse intrinsic pontine glioma)
- ESMART (All tumors)
- MEMMAT (Medulloblastoma)
- BEACON (Neuroblastoma)
- CELYVIR (All solid tumors)
- CRISP (ALK mutated tumors)
4 OBSERVATIONAL STUDIES AND REGISTRIES (INDICATION)
- SEHOP-PETHEMA (Acute lymphoblastic leukemia)
- LAL 2005/2008 (Acute lymphoblastic leukemia)
- LNH 2018 (Non-Hodgkin Lymphoma)
- LMA SHOP (Acute myeloid leukemia)
PHASE 1-2 CLINICAL TRIALS WHERE INSURANCE IS COVERED
(Phase 1=1; Phase II=6)
- ESMART (Phase I)
- VINILO (Phase II)
- BIOMEDE (Phase II)
- MEMMAT (Phase II))
- BEACON (Phase II)
- CELYVIR (Phase II)
- CRISP (Phase II)
Integral Support
(12 studies)
8 CLINICAL TRIALS (INDICATION)
- EURONET PHL-C2 (Hodgkin Lymphoma)
- NOPHO-DBH-AML 2012 (Acute myeloid leukemia)
- IntReALL HR 2010 (Acute lymphoblastic leukemia)
- IntReALL SR 2010 (Acute lymphoblastic leukemia)
- ALL SCTped Forum 2012 (Acute lymphoblastic leukemia and stem cell transplant)
- SIOP Ependymoma II (Ependymoma)
- LBL-2018 (Lymphoblastic lymphoma)
- ESPHALL 2017 (Philadelphia positive acute lymphoblastic leukemia)
4 OBSERVATIONAL STUDIES  AND REGISTRIES (INDICATION)
- I-CML-PED Registry (Chronic myeloid leukemia)
- INTERFANT-06 (Infant acute lymphoblastic leukemia)
- IBFM AMBI 2018 (Ambigous and mixed lineage acute lymphoblastic leukemia)
- UMBRELLA (Wilms tumour and other malignant renal tumors)
Fig. 3  ECLIM-SEHOP clinical trial and observational studies portfolio
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Discussion
Clinical trials are used to determine the most effective and 
safe treatments for a given disease. In childhood cancer, 
each trial aims at improving survival, reducing side effects 
or long-term sequelae of treatment. In some countries of 
Western Europe, participation in clinical trials has become 
the standard of care in children and adolescents with cancer.
To date, infrastructure and support to facilitate partici-
pation in academic international multicenter collaborative 
clinical trials in pediatric cancer in Spain has not matched 
the same standards than other European countries such as 
France, Germany or the United Kingdom. Initiatives like 
SCReN (Spanish Clinical Research Network, http://www.
scren .es) provide excellent support to some clinical trials, 
but so far, have had limited resources and could not cover all 
the needs from the pediatric oncology community.
Historically, Spain has not been able to participate in 
multiple international clinical trials because of the above-
mentioned lack of resources and infrastructure to adapt to 
modern regulatory standards and provide good quality data. 
For some other studies, the time to setup the trials in our 
country has been so long due to administrative barriers that 
the trials were completed or nearly completed internationally 
by the time the trials were open.
The participation of our country in international clinical 
trials makes a huge contribution to our society for several 
reasons: (1) clinical trials evaluate more novel strategies and 
offer access to new treatments, (2) treatment within clini-
cal trials is always done in centers with proven experience, 
with less variability and greater control of toxicities that may 
appear, being safer than being treated outside trials, (3) clini-
cal trials allow to advance scientific knowledge and improve 
results of childhood cancer therapy and (4) collaboration at 
national and international level is essential to improve the 
results in such a significant group of rare diseases.
In our country, survival of childhood cancer has improved 
significantly in recent years, but the data are still below that 
of other neighboring countries in Western Europe such as 
France, the United Kingdom or Italy. For example, in the 
case of lymphoblastic leukemia, the EUROCARE5 study 
and a national study of the Registro Nacional de Tumores 
Infantiles (RETI-SEHOP) have reported lower survival rates 
in Spain (83%) compared to France (90%), Germany (90%), 
Italy (89%) or United Kingdom (88%) [4, 18].
With the implementation of the first European Clinical 
Trial Directive in 2001, the development and conduct of aca-
demic clinical trials entailed a significant burden of admin-
istrative duties at the international, national and local levels. 
These tasks surely exceed the capacity of individual clinical 
investigators in charge of each study as national coordina-
tors. It was, therefore, necessary to provide support for all 
the new international clinical trials that are being imple-
mented and maintain a stable and organized infrastructure 
to carry out these activities.
Since 2004, there has been a progressive improvement in 
our performance metrics as a country in clinical trial setup 
and conduct [19]. This positive change is due, among other 
factors, to changes in current legislation, learning curve of 
participating institutions and ethics committees.
Most of the activity in oncology clinical trials carried out 
in Spain is dependent on the pharmaceutical industry, which 
is surely more focused on new drug development, rather than 
on standard clinical practice, procedures such as transplant 
or surgery, radiotherapy or medical devices, and does not 
necessarily respond to the capabilities and opportunities of 
the clinical and academic research ecosystem, nor to the epi-
demiological reality of cancer in our country [20]. In Spain, 
76% of this activity is industry sponsored, compared to that 
of 49% in France, 56% in the Netherlands, 62% in Italy or 
65% in the United Kingdom. To improve our capacity to 
innovate in the field of clinical research, and achieve the goal 
that every child and adolescent in our country can potentially 
be included in a clinical trial, it is necessary for the Spanish 
public institutions to have greater funding and capabilities 
to develop more academic trials and implement collabora-
tive international plans. ECLIM-SEHOP is supported with 
funds from competitive grants from the Asociación Española 
Contra el Cancer (AECC) and Fundación Inocente as well as 
other non-competitive contributions from non-profit organi-
zations, mainly Federación Española de Padres de Niños con 
Cáncer, Asociación Pablo Ugarte y Fundación Mar, and, 
therefore, in constant need of identifying financial resources 
to make it sustainable. Still, our clinical trial setup metrics 
Table 2  ECLIM-SEHOP 
recruitment metrics from all 8 
clinical trials included (5 open, 
3 in setup)
CA competent authorities
Metric Median (range), in months
Time from submission to CA approval (7 trials) 3.0 (0.6– 8.6)
Time from CA approval to first site open (5 trials) 9.1 (1.2–38.5)
Time from CA approval to > 50% of the sites open (4 trials) 9.7 (2.5–43.4)
Time from first site open to first patient recruited (4 trials) 2.3 (0.8–3.5)
Time from CA submission to first patient recruited (4 trials) 11.4 (8.7–49.9)
Time from first international site open to first Spanish site open (4 trials) 41.5 (14.7–62)
1769Clinical and Translational Oncology (2019) 21:1763–1770 
1 3
can be improved by far. Hopefully, the data provided here 
will serve as a baseline for future comparisons and, with 
time, the timelines to open clinical trial will shorten, so that 
these new advances reach our patients as soon as possible.
In summary, thanks to the enormous work and generosity 
of SEHOP members that are leading on these clinical tri-
als and all stakeholders involved in this process, including 
parents, patients and other healthcare professionals, together 
with the help of the ECLIM-SEHOP platform we will facili-
tate Spanish children and adolescents diagnosed with cancer 
and blood disorders to access state-of-the-art diagnostic and 
therapeutic strategies, and in this way continue to improve 
survival rates and decreasing the side effects of long-term 
treatment.
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